Table 1 Clinical, peripheral blood and bone marrow features of myelodysplastic/myeloproliferative neoplasms-unclassifiable (MDS/MPN-U) with i(17q) [study group] with MDS/MPN-U cases without isolated i(17q) [control group].
MDS/MPN-U with iso i(17q), n = 29 | MDS/MPN-U without i(17q), n = 63 | P | |
|---|---|---|---|
Age, years (median, range) | 67 (41–88) | 71 (60–88) | 0.005 |
Male gender | 13 (45%) | 33 (52%) | NS |
Splenomegaly (frequency) | 20 (69%) | 8 (16%) | 0.001 |
Peripheral blood (PB) counts | |||
Hemoglobin | 9.4 (5.8–15.1) | 10.1 (6.8–13.6) | 0.037 |
White blood cell counts | 13.6 (1.2–119) | 19.4 (1.5–98.7) | NS |
Platelet count × 109/L (median, range) | 103 (16–1000) | 142 (11–1040) | NS |
ANC × 109/L (median, range) | 4.6 (0.3–50) | 15.8 (0.74–79.9) | 0.008 |
PB blasts (median, range) | 2 (0–13) | 0 (0–13) | 0.057 |
Bone marrow (BM) morphologic features | |||
BM blasts% (median, range) | 4 (0–18) | 2 (0–17) | NS |
Dyserythropoiesis | 9/22 (41%) | 29/57 (51%) | NS |
Dysgranulopoiesis | 13/22 (59) | 38/58 (66%) | NS |
Dysmegakaryopoiesis | 22/22 (100%) | 41/56 (73%) | 0.008 |
Myelofibrosis (MF) grade 2/3 | 9/22 (41%) | 15/57 (26%) | NS |
Treatment data | n = 28 | n = 58 | |
Supportive | 7 (25%) | 12 (21%) | NS |
Chemotherapy only | 3 (11%) | 5 (9%) | NS |
Hypomethylating agents (HMA) | 13 (47%) | 25 (43%) | NS |
HMA plus chemotherapy/others | 3 (11%) | 9 (14%) | NS |
Othersa | 2 (7%) | 3 (5%) | NS |
Allogeneic stem cell transplant | 6 of 28 (21%) | 5 of 58 (9%) | NS |
